Key facts
- Notable investors include Sofinnova Partners, Invivo Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Signadori Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Signadori Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Signadori Bio
Operator of a biopharmaceutical company intended to develop a cell therapy approach to treat cancer. The company focuses on next-generation cellular immunotherapy for cancer cures, enabling doctors to find other solutions for defeating cancer cells.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2025
- Employees
- 4
- Website
- signadori.bio/
- Ownership
- Privately Held (backing)
Signadori Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Signadori Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Signadori Bio in its N-PORT filings yet. We sweep new filings monthly.